6533b823fe1ef96bd127ebaa

RESEARCH PRODUCT

Seven-day fasting as a multimodal complex intervention for adults with type 1 diabetes: Feasibility, benefit and safety in a controlled pilot study.

Bettina BergerAndrea BaumannDiana KöblösJohannes SimstichRainer StangeEkkehart JenetzkyDavid D. MartinAndreas MichalsenKurt-martin Schmelzer

subject

0301 basic medicineAdultBlood Glucosemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismPilot ProjectsType 2 diabetes03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansType 1 diabetes030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryFastingmedicine.diseaseKetoacidosisBlood pressureDiabetes Mellitus Type 1Diabetes Mellitus Type 2Ketone bodiesQuality of LifeFeasibility StudiesKetosisMetabolic syndromebusinessBody mass index

description

Abstract Objectives Intermittent as well as prolonged fasting are receiving considerable attention and appear favorable in conditions such as metabolic syndrome, type 2 diabetes, and rheumatic diseases. Fasting for individuals with type 1 diabetes (T1D) is generally considered too risky. However, the ability and possibility to change from carbohydrate- to ketone-based fuel supply might be relevant for individuals with T1D. The aim of this patient-led research was to investigate the feasibility, benefit, and safety of a 7-d multimodal fasting intervention in individuals with T1D. Methods This was a non-randomized controlled pilot study, with 20 participants with T1D and 10 without the disease. Data acquisition took place before, after, and 4 mo after the intervention and daily during intervention. Results Of the individuals with T1D, 19 finished fasting. A mean β-hydroxybutyrate as representative ketone body increased to 2.8 ± 1.9 mmol/L on day 7; whereas average glucose remained between 4.9 (±1.5) and 7.5 (±2.3) mmol/L (89 ± 27 and 136 ± 40 mg/dL). Mean daily insulin dose was adjusted from 24.4 (3–50) IU on the day before fasting to 7.6 (0–26.7) IU on day 7. Quality of life (WHO-5) normalized from 54 (±4.4) to 68.8 (±15; P = 0.01) after fasting. There was a decrease from before until the follow-up 4 mo later of weight from 77.6 (±20.4) to 76.6 (±20.9) kg (P = 0.023) and for body mass index from 27.68 (±7.04) to 26.74 (±7.15) kg/m2 (P = 0.008). Diastolic blood pressure increased from 69.75 (±11.41) to 75.74 (±8.42) mm Hg (P = 0.028) and stayed in a healthy range on average. Fasting-related side effects were all temporary, and slightly more prevalent in those with type 1 diabetes compared with the reference group. Conclusions This study demonstrated the feasibility, benefits, and safety aspects of a 7-d fast in adults with T1D.

10.1016/j.nut.2021.111169https://pubmed.ncbi.nlm.nih.gov/33636417